Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pieter Stolk

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Contraception|October 22, 2008
Impact analysis of the discontinuation of reimbursement: the case of oral contraceptivesPieter Stolk, Sebastian Schneeweiss, Hubert G M Leufkens, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
Variable access to clopidogrel in a harmonized EU marketPieter Stolk, Svetlana V Belitser, Hubert G M Leufkens, et al.
Drug Discovery Today|March 15, 2017
Factors related to drug approvals: predictors of outcome?Lawrence Liberti, Alasdair Breckenridge, Jarno Hoekman, et al.
Nature Reviews. Drug Discovery|February 2, 2010
Pharmaceutical sciences in 2020Daan Crommelin, Pieter Stolk, Luc Besançon, et al.
Therapeutic Innovation & Regulatory Science|February 7, 2022
Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences?Kevin Klein, Pieter Stolk, Pär Tellner, et al.
The Annals of Pharmacotherapy|November 25, 2003
Meta-analysis of placebo rates in major depressive disorder trialsPieter Stolk, Maarten J Ten Berg, Michiel E H Hemels, et al.
Frontiers in Pharmacology|April 20, 2017
FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization TimelinesLawrence Liberti, Magda Bujar, Alasdair Breckenridge, et al.
The Oncologist|May 8, 2015
Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing ApplicationsLawrence Liberti, Pieter Stolk, James Neil McAuslane, et al.
British Journal of Clinical Pharmacology|February 26, 2008
Gap in publication of comparative information on new medicinesJohan C F van Luijn, Pieter Stolk, Frank W J Gribnau, et al.
Orphanet Journal of Rare Diseases|December 17, 2009
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot studyPieter Stolk, Harald E Heemstra, Hubert G M Leufkens, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Contraception|October 22, 2008
Impact analysis of the discontinuation of reimbursement: the case of oral contraceptivesPieter Stolk, Sebastian Schneeweiss, Hubert G M Leufkens, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2008
Variable access to clopidogrel in a harmonized EU marketPieter Stolk, Svetlana V Belitser, Hubert G M Leufkens, et al.
Drug Discovery Today|March 15, 2017
Factors related to drug approvals: predictors of outcome?Lawrence Liberti, Alasdair Breckenridge, Jarno Hoekman, et al.
Nature Reviews. Drug Discovery|February 2, 2010
Pharmaceutical sciences in 2020Daan Crommelin, Pieter Stolk, Luc Besançon, et al.
Therapeutic Innovation & Regulatory Science|February 7, 2022
Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences?Kevin Klein, Pieter Stolk, Pär Tellner, et al.
The Annals of Pharmacotherapy|November 25, 2003
Meta-analysis of placebo rates in major depressive disorder trialsPieter Stolk, Maarten J Ten Berg, Michiel E H Hemels, et al.
Frontiers in Pharmacology|April 20, 2017
FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization TimelinesLawrence Liberti, Magda Bujar, Alasdair Breckenridge, et al.
The Oncologist|May 8, 2015
Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing ApplicationsLawrence Liberti, Pieter Stolk, James Neil McAuslane, et al.
British Journal of Clinical Pharmacology|February 26, 2008
Gap in publication of comparative information on new medicinesJohan C F van Luijn, Pieter Stolk, Frank W J Gribnau, et al.
Orphanet Journal of Rare Diseases|December 17, 2009
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot studyPieter Stolk, Harald E Heemstra, Hubert G M Leufkens, et al.
Pageof 4